Wills Eye Institute.
Ophthalmology. 2010 Jun;117(6):1087-1093.e3. doi: 10.1016/j.ophtha.2009.10.040. Epub 2010 Mar 17.
To evaluate vitrectomy for diabetic macular edema (DME) in eyes with at least moderate vision loss and vitreomacular traction.
Prospective cohort study.
The primary cohort included 87 eyes with DME and vitreomacular traction based on investigator's evaluation, visual acuity 20/63-20/400, optical coherence tomography (OCT) central subfield >300 microns and no concomitant cataract extraction at the time of vitrectomy.
Surgery was performed according to the investigator's usual routine. Follow-up visits were performed after 3 months, 6 months (primary end point), and 1 year.
Visual acuity, OCT retinal thickening, and operative complications.
At baseline, median visual acuity in the 87 eyes was 20/100 and median OCT thickness was 491 microns. During vitrectomy, additional procedures included epiretinal membrane peeling in 61%, internal limiting membrane peeling in 54%, panretinal photocoagulation in 40%, and injection of corticosteroids at the close of the procedure in 64%. At 6 months, median OCT central subfield thickness decreased by 160 microns, with 43% having central subfield thickness <250 microns and 68% having at least a 50% reduction in thickening. Visual acuity improved by > or =10 letters in 38% (95% confidence interval, 28%-49%) and deteriorated by > or =10 letters in 22% (95% confidence interval, 13%-31%). Postoperative complications through 6 months included vitreous hemorrhage (5 eyes), elevated intraocular pressure requiring treatment (7 eyes), retinal detachment (3 eyes), and endophthalmitis (1 eye). Few changes in results were noted between 6 months and 1 year.
After vitrectomy performed for DME and vitreomacular traction, retinal thickening was reduced in most eyes. Between 28% and 49% of eyes with characteristics similar to those included in this study are likely to have improvement of visual acuity, whereas between 13% and 31% are likely to have worsening. The operative complication rate is low and similar to what has been reported for this procedure. These data provide estimates of surgical outcomes and serve as a reference for future studies that might consider vitrectomy for DME in eyes with at least moderate vision loss and vitreomacular traction.
评估玻璃体切割术治疗伴有至少中度视力丧失和玻璃体黄斑牵引的糖尿病性黄斑水肿(DME)。
前瞻性队列研究。
主要队列包括 87 只眼睛,这些眼睛基于研究者的评估患有 DME 和玻璃体黄斑牵引,视力 20/63-20/400,光学相干断层扫描(OCT)中央凹 300 微米以上,并且在玻璃体切割术时没有同时进行白内障摘除。
根据研究者的常规程序进行手术。术后 3 个月、6 个月(主要终点)和 1 年进行随访。
视力、OCT 视网膜增厚和手术并发症。
在基线时,87 只眼中的中位数视力为 20/100,中位数 OCT 厚度为 491 微米。在玻璃体切割术中,附加程序包括 61%的内界膜剥除、54%的内界膜剥除、40%的全视网膜光凝以及 64%的皮质类固醇注射。在 6 个月时,中位数 OCT 中央凹厚度减少了 160 微米,43%的中央凹厚度<250 微米,68%的厚度减少了 50%以上。38%(95%置信区间,28%-49%)的视力提高了>或=10 个字母,22%(95%置信区间,13%-31%)的视力恶化了>或=10 个字母。术后 6 个月的并发症包括玻璃体积血(5 只眼)、需要治疗的眼压升高(7 只眼)、视网膜脱离(3 只眼)和眼内炎(1 只眼)。在 6 个月和 1 年之间,结果的变化很小。
对于 DME 和玻璃体黄斑牵引进行玻璃体切割术后,大多数眼睛的视网膜增厚减少。类似于本研究纳入标准的眼睛中,28%至 49%的眼睛可能会提高视力,而 13%至 31%的眼睛可能会恶化。手术并发症发生率较低,与该手术的报告相似。这些数据提供了手术结果的估计,并为未来可能考虑在至少中度视力丧失和玻璃体黄斑牵引的情况下进行 DME 玻璃体切割术的研究提供了参考。